Gruson Damien, Hermans Michel P, Ferracin Benjamin, Ahn Sylvie A, Rousseau Michel F
a Pôle de Recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique , Cliniques Universitaires St-Luc and Université Catholique de Louvain , Brussels , Belgium ;
b Department of Laboratory Medicine , Cliniques Universitaires St-Luc and Université Catholique de Louvain , Brussels , Belgium ;
Scand J Clin Lab Invest. 2016 Sep;76(5):411-6. doi: 10.1080/00365513.2016.1190863. Epub 2016 Jun 13.
Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of endothelial growth factors, such as placental growth factor (PlGF), which modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients with heart failure (HF) and its relationship to adverse cardiovascular (CV) events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels were also determined in healthy volunteers and patients with type 2 diabetes mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in comparison to T2DM patients or healthy subjects (p < 0.01). Concentration of sFlt-1 was related to HF severity (p < 0.001) and was correlated to NT-proBNP (ρ = 0.37, p < 0.01), soluble ST2 (ρ = 0.52, p < 0.01), Galectin-3 (ρ = 0.38, p < 0.01), aldosterone (ρ = 0.25, p = 0.01) and PTH(1-84) (ρ = 0.38, p < 0.01). Furthermore, sFlt-1 levels were associated to long-term CV risk. These results suggest a potential role of sFlt-1 in HF and its potential role as biomarker of CV risk.
可溶性fms样酪氨酸激酶-1(sFlt-1)是内皮生长因子的内源性抑制剂,如胎盘生长因子(PlGF),其可调节心血管(CV)重塑。我们测定了心力衰竭(HF)患者的sFlt-1水平及其与不良心血管(CV)事件和心血管风险生物标志物的关系。还测定了健康志愿者和2型糖尿病(T2DM)患者的sFlt-1水平和PlGF水平。与T2DM患者或健康受试者相比,HF患者的sFlt-1和PlGF水平明显升高(p<0.01)。sFlt-1浓度与HF严重程度相关(p<0.001),并与NT-proBNP(ρ=0.37,p<0.01)、可溶性ST2(ρ=0.52,p<0.01)、半乳糖凝集素-3(ρ=0.38,p<0.01)、醛固酮(ρ=0.25,p=0.01)和甲状旁腺激素(1-84)(ρ=0.38,p<0.01)相关。此外,sFlt-1水平与长期CV风险相关。这些结果提示sFlt-1在HF中的潜在作用及其作为CV风险生物标志物的潜在作用。